KAT6 Inhibitor Compounds for Selective Breast Cancer Treatment
Solution Overview
Problem
KAT6 proteins, particularly KAT6A, are overexpressed in breast cancer, contributing to tumorigenesis and cancer progression, necessitating the development of effective inhibitors to treat this condition.
Innovation Solution
Development of compounds of Formula (I) and their pharmaceutically acceptable salts, deuterated analogs, or N-oxides, which act as KAT6 inhibitors to regulate lysine acetylation and potentially inhibit breast cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If KAT6 inhibitors are developed to treat breast cancer, then therapeutic efficacy is improved, but drug specificity and selectivity become critical challenges
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that target particular regions or characteristics of the KAT6 protein structure. The compounds are engineered to interact with specific amino acid residues or structural domains of KAT6, ensuring selective inhibition while avoiding off-target effects on other proteins with similar functions.
Solution Approach 2:
The patent employs parameter changes by systematically modifying chemical parameters of the inhibitor molecules, such as substituent groups, molecular weight, lipophilicity, and binding affinity. These parameter optimizations enable the compounds to achieve high selectivity for KAT6 over other lysine acetyltransferases, thereby improving therapeutic efficacy while minimizing harmful off-target effects.
2Object-affected harmful factors
If complex compound structures are designed to enhance KAT6 inhibition, then selectivity is improved, but ease of manufacture deteriorates
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules or building blocks that can be independently synthesized and then assembled. This modular approach allows for systematic optimization of selectivity through combinatorial chemistry while maintaining relative ease of manufacture by using standardized synthetic protocols for each module.
Solution Approach 2:
The patent employs universality by designing core structural scaffolds that can serve multiple purposes: they provide the necessary selectivity for KAT6 inhibition while also being amenable to various synthetic routes and scalable manufacturing processes. The universal core structures allow for diverse substituent modifications without requiring complete resynthesis of the entire molecule.
Data Source
AI summary
Disclosed herein are compounds used as inhibitors of KAT6 and pharmaceutical compositions comprising the compounds. Also disclosed are methods for treating a disorder or disease responsive to the inhibition of KAT6 activity in a subject. In an embodiment, the compounds are of formula (I):or a pharmaceutically acceptable salt thereof, or a deuterated analog thereof, or an N-oxide thereof, or a tautomer thereof, wherein values for the variables (e.g., ring B, A1, A2, A3, A4, A5, X1, L, R62, R63, R64, R7, and n) are disclosed herein.